AI SaaS Development in Boston, Massachusetts

Life Sciences / Regulatory Affairs

A Cambridge-based startup (3 founders — 2 former FDA regulatory affairs professionals and 1 former biotech VP of Regulatory) had identified a significant pain point in the pharmaceutical industry: regulatory intelligence. Every pharmaceutical and biotech company needs to monitor FDA regulatory activity — new guidances, advisory committee meetings, approval decisions, warning letters, and changes to inspection standards — that affects their development programs and commercial products. The current approach: regulatory affairs teams manually monitored the FDA website, subscribed to regulatory news services (RAPS, FDAnews, Regulatory Focus), and maintained spreadsheets tracking relevant regulatory developments. For a company with 5+ development programs across multiple therapeutic areas, this monitoring consumed 20-30 hours per week of senior regulatory affairs professionals' time ($150-250/hr loaded cost). The founders had built a prototype (Python scripts that scraped FDA's website and used basic NLP to categorize documents) that demonstrated the concept. They needed an engineering partner to build the prototype into a production SaaS platform that could: process 5,000+ FDA documents per month across guidance documents, Federal Register notices, advisory committee transcripts, approval packages, and warning letters; use AI to classify each document by therapeutic area, regulatory topic, and relevance to specific drug development stages; deliver personalized regulatory alerts to each customer based on their product portfolio and development stage; and provide a searchable regulatory intelligence database with AI-powered question answering. The founders had raised $1.8M in seed funding (led by Polaris Partners, Boston) and needed a production platform within 5 months to convert 4 design partner biotech companies into paying customers before their next fundraise.

We built the regulatory intelligence SaaS platform over 18 weeks (delivering ahead of the 5-month target). Data Ingestion Engine: automated collection of FDA documents from 14 source channels — FDA.gov (guidances, approval letters, warning letters, 483 observations), Federal Register (proposed and final rules), ClinicalTrials.gov (regulatory-relevant trial updates), FDA advisory committee calendars and transcripts, Congressional hearing transcripts related to FDA oversight, and EU EMA publications (for companies with global regulatory strategies). Each document was processed through a multi-stage pipeline: format extraction (parsing PDF, HTML, and XML into clean text), metadata extraction (publication date, document type, issuing office, docket number), entity recognition (identifying drug names, company names, therapeutic areas, and regulatory topics), and classification (categorizing by therapeutic area using a fine-tuned BERT model trained on 45,000 historically classified FDA documents from the founders' regulatory careers). AI-Powered Relevance Scoring: each customer configured their regulatory profile — therapeutic areas, development stage, drug modalities, and specific regulatory topics they monitored. The AI engine scored every incoming document against each customer's profile, generating a personalized relevance score that determined alert priority. The relevance model was fine-tuned on regulatory affairs professionals' historical document assessments, achieving 93% agreement with senior regulatory professionals on document relevance classification. Regulatory Intelligence Dashboard: the SaaS platform's frontend (built in Next.js) provided: personalized regulatory feed (a prioritized timeline of regulatory developments relevant to the customer, updated daily), document analysis workspace (AI-generated summaries of complex regulatory documents — a 200-page FDA guidance summarized into a 2-page executive brief with key implications highlighted), regulatory Q&A (RAG-powered question answering — "What are the current FDA expectations for AI/ML in diagnostic devices?" answered with citations to specific guidance documents, advisory committee discussions, and approval precedents), and competitive intelligence (tracking regulatory activity related to competitor programs — warning letters, complete response letters, and approval timelines for competing products). Multi-Tenant Architecture: built for scale from day one — each customer's regulatory profile, alert preferences, and document annotations were isolated in a multi-tenant PostgreSQL database with row-level security. The AI processing pipeline shared infrastructure across customers (cost efficient) while maintaining data isolation (each customer's proprietary annotations and search queries were never visible to other customers). Compliance: SOC 2 Type I readiness (implemented during development, with Type II audit scheduled for month 8). The platform did not handle PHI or clinical trial data, simplifying compliance — but the founders planned to add clinical data features in the future, so we designed the architecture to support HIPAA and 21 CFR Part 11 compliance without rearchitecting.

The platform launched to the 4 design partner biotech companies in week 16, 2 weeks ahead of the 5-month target. All 4 design partners converted to paying customers within 6 weeks of launch (annual contract values: $48K, $72K, $96K, and $120K — totaling $336K in initial ARR, priced based on company size and number of monitored therapeutic areas). The relevance scoring model achieved 93% agreement with senior regulatory professionals — significantly better than the 67% agreement achieved by the founders' Python prototype, validating the investment in proper AI engineering. Regulatory affairs teams at the 4 customer companies reported: monitoring time reduced from 20-30 hours/week to 3-5 hours/week (an 80-85% reduction), faster identification of regulatory developments affecting their programs (average 2.3 days faster than manual monitoring), and the regulatory Q&A feature replacing 30-40% of external regulatory counsel inquiries ($500-1,000/hr consulting fees). Based on the initial customer traction and product demonstration, the company closed a $6.5M Series A led by Atlas Venture (Boston) 4 months after platform launch — the production-quality SaaS platform and paying customer base were cited as the primary differentiation from competing pitches that had only prototypes. Development cost: $245,000 (18 weeks). Initial ARR: $336,000. Series A raised: $6.5M at $32M pre-money valuation. ROI for the founders: the $245K development investment created a company valued at $32M within 8 months of engagement start — a 130x return on development investment.